In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2606-2617

  Pellizzari Tregno, Francesca ^a   Sau, Andrea ^a   Pezzola, Silvia ^a   Geroni, Cristina ^b   Lapenta, Caterina ^c   Spada, Massimo ^c   Filomeni, Giuseppe ^a   Bonanno, Elena ^a   Federici, Giorgio ^d   Caccuri, Anna Maria ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Antitumour drug; GSTP1 1 (Glutathione S transferase Pi); JNK (c Jun N Terminal Kinase); Melanoma; NBDHEX (6 (7 nitro 2,1,3 benzoxadiazol 4 ylthio)hexanol)

Indexed keywords

6 (7 NITRO 2,1,3 BENZOXADIAZOL 4 YLTHIO)HEXANOL; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE S-TRANSFERASE PI; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MELANOMA; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; OXADIAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 69349088785     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.033     Document Type: Article

References (31)

1. Pipeline insight: cancer overview - gastrointestinal, skin, sarcomas. Datamonitor Pharmaceutical Report; 2008. p. 118-23.
2. Helmbach H., Rossmann E., Kern M.A., and Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 93 5 (2001) 617-622
3. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 8 (2002) 2045-2052
4. Middleton M.R., Lorigan P., Owen J., et al. A randomised phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82 (2000) 1158-1162
5. Quirt I., Verma S., Petrella T., Bak K., and Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. The Oncologist 12 (2007) 1114-1123
6. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
7. Turella P., Cerella C., Filomeni G., et al. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 65 9 (2005) 3751-3761
8. Townsend D.M., and Tew K.D. The role of glutathione-S transferase in anti-cancer drug resistance. Oncogene 22 (2003) 7369-7375
9. Depeille P., Cuq P., Passagne I., Evrard A., and Vian L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 93 2 (2005) 216-223
10. Awasthi Y.C., Sharma R., Yadav S., Dwivedi S., Sharma A., and Awasthi S. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr Drug Metab 8 4 (2007) 315-323
11. Colone M., Calcabrini A., Toccacieli L., et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?. J Invest Dermatol 128 4 (2008) 957-971
12. Turella P., Filomeni G., Dupuis M.L., et al. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro- 2, 1, 3-benzoxadiazol-4-ylthio) hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J Biol Chem 281 (2006) 23725-23732
13. Filomeni G., Turella P., Dupuis M.L., et al. 6-(7-Nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther 7 2 (2008) 371-379
14. Ascione A., Cianfriglia M., Dupuis M.L., et al. The glutathione S-transferase 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Cancer Chemother Pharmacol 64 2 (2009) 419-424
15. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11 8 (2004) 915-923
16. Ricci G., De Maria F., Antonini G., et al. 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 280 28 (2005) 26397-26405
17. Lugini L., Lozupone F., Matarrese P., et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of Ezrin. Lab Invest 83 11 (2003) 1555-1567
18. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
19. Pasello M., Michelacci F., Scionti I., et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68 (2008) 6661-6668
20. Lopez-Bergami P., Huang C., Goydos J.S., et al. Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell 11 (2007) 447-460
21. Wong S.H., Shih R.S., Schoene N.W., and Lei K.Y. Zinc-induced G2/M blockage is p53 and p21 dependent in normal human bronchial epithelial cells. Am J Physiol Cell Physiol 294 6 (2008) C1342-C1349
22. Selvendiran K., Tong L., Vishwanath S., et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282 39 (2007) 28609-28618
23. Kim G.Y., Mercer S.E., Ewton D.Z., Yan Z., Jin K., and Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(CIP1) by phosphorylation. J Biol Chem 277 33 (2002) 29792-29802
24. Bunz F., Dutriaux A., Lengauer C., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 5393 (1998) 1497-1501
25. Whitfield M.L., George L.K., Grant G.D., and Perou C.M. Common markers of proliferation. Nat Rev Cancer 6 2 (2006) 99-106
26. Rozenblat S., Grossman S., Bergman M., Gottlieb H., Cohen Y., and Dovrat S. Induction of G2/M arrest and apoptosis by sesquiterpene lactones in human melanoma cell lines. Biochem Pharmacol 75 2 (2008) 369-382
27. Eberle J., Kurbanov B.M., Hossini A.M., Trefzer U., and Fecker L.F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat 10 6 (2007) 218-234
28. Soengas M.S., Capodieci P., Polsky D., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409 6817 (2001) 207-211
29. Leiter U., Schmid R.M., Kaskel P., Peter R.U., and Krähn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292 5 (2000) 225-232
30. Mhaidat N.M., Zhang X.D., Jiang C.C., and Hersey P. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 13 4 (2007) 1308-1314
31. Zhu B.K., Wang P., Zhang X.D., et al. Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anticancer Drugs 19 2 (2008) 189-200